Schizophrenia and depression

Medical Journal of Australia

Volumn 1, Issue , 2012, Pages 36-39

  Bosanac, Peter ^a,b   Castle, David J ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; ZIPRASIDONE;

ARTICLE; COGNITIVE THERAPY; DEPRESSION; DSM-IV-TR; GENERAL PRACTITIONER; HEALTH SERVICE; HUMAN; LOW DRUG DOSE; MOOD DISORDER; PHYSICAL CONSTITUTION AND HEALTH; SCHIZOPHRENIA; SUICIDE;

EID: 84889039092     PISSN: 0025729X     EISSN: 13265377     Source Type: Journal    
DOI: 10.5694/mjao12.10516     Document Type: Article

References (30)

1. Buckley, PF, Miller, BJ, Lehrer, DS, Castle, DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull 2009; 35: 383-402.
2. Keefe, RSE, Fenton, WS. How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr Bull 2007; 33: 912-920.
3. Morgan, VA, Waterreus, A, Jablensky, A, et al. People living with psychotic illness 2010: report on the second Australian national survey. Canberra: Department of Health and Ageing, 2011. http://www.health.gov.au/internet/main/publishing.nsf/content/353E10EE88736 E02CA2579500005C211/$File/psych10.pdf (accessed Jun 2012).
4. Cantor-Graae, E, Nordstrom, LG, McNeil, TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001; 48: 69-82.
5. Moore, E, Mancuso, SG, Slade, T, et al. The impact of alcohol and illicit drugs on people with psychosis: the second Australian national survey of psychosis. Aust N Z J Psychiatry 2012; 46: 864-878. doi: 10.1177/ 0004867412443900.
6. Siris, SG. Depression in schizophrenia: perspective in the era of “atypical” antipsychotic agents. Am J Psychiatry 2000; 157: 1379-1389.
7. Lako, IM, Taxis, K, Bruggeman, R, et al. The course of depressive symptoms and prescribing patterns of antidepressants in schizophrenia in a one-year follow-up study. Eur Psychiatry 2012; 27: 240-244.
8. Saha, S, Chant, D, McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry 2007; 64: 1123-1131.
9. Hayes, RD, Chang, CK, Fernandes, A, et al. Associations between symptoms and all-cause mortality in individuals with serious mental illness. J Psychosom Res 2012; 72: 114-119.
10. Mulholland, C, Cooper, S. The symptom of depression in schizophrenia and its management. Adv Psychiatr Treat 2000; 6: 169-177.
11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Publishing, 2000.
12. Castle, D, Bosanac, P. Depression and schizophrenia. Adv Psychiatr Treat 2012; 18: 280-288.
13. Dixon, LB, Dickerson, F, Bellack, AS, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010; 36: 48-70.
14. Jones, C, Hacker, D, Cormac, I, et al. Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cochrane Database Syst Rev 2012; (4): CD008712. doi: 10.1002/14651858.CD008712.pub2.
15. Sahoo, S, Mohapatra, PK. Demoralization syndrome: a conceptualization. Orissa J Psychiatry 2009; 16 (Sep): 18-20.
16. Siris, SG, Bench, C. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. 2nd ed. Oxford: Blackwell Science, 2003: 142-167.
17. Whitehead, C, Moss, S, Cardno, A, et al. Antidepressants for people with both schizophrenia and depression. Cochrane Database Syst Rev 2002; (2): CD002305. doi: 10.1002/14651858.CD002305.
18. Zisook, S, Kasckow, JW, Lanouette, NM, et al. Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J Clin Psychiatry 2010; 71: 915-922.
19. Tiihonen, J, Suokas, JT, Suvisaari, JM, et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69: 476-483.
20. Addington, DE, Mohamed, S, Rosenheck, RA, et al. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. J Clin Psychiatry 2011; 72: 75-80.
21. Rybakowski, JK, Vansteelandt, K, Szafranski, T, et al; EUFEST Study Group. Treatment of depression in first episode of schizophrenia: results from EUFEST. Eur Neuropsychopharmacol 2012; May 22 [Epub ahead of print].
22. Lee, KU, Jeon, YW, Lee, HK, Jun, T Y. Efficacy and safety of quetiapine for depressive symptoms in patients with schizophrenia. Hum Psychopharmacol 2009; 24: 447-452.
23. Kasper, S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety 2004; 20: 44-47.
24. Emsley, RA, Buckley, P, Jones, AM, Greenwood, MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol 2003; 17: 210-215.
25. Dollfus, S, Olivier, V, Chabot, B, et al. Olanzapine versus risperidone in the treatment of post-psychotic depression in schizophrenic patients. Schizophr Res 2005; 78: 157-159.
26. Kinon, BJ, Lipkovich, I, Edwards, SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006; 26: 157-162.
27. Furtado, VA, Srihari, V, Kumar, A. Atypical antipsychotics for people with both schizophrenia and depression. Cochrane Database Syst Rev 2008; (1): CD005377. doi: 10.1002/14651858.CD005377.pub2.
28. Meltzer, H Y, Okayli, G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190.
29. Walker, AM, Lanza, LL, Arellano, F, Rothman, KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677.
30. Meltzer, H Y, Alphs, L, Green, AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.